SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris announced the publication of a real-world study validating…

Pharvaris N.V. · PRESS-RELEASE filed Mar 11, 2026 at 06:50 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 11, 2026 at 06:50 ET

Pharvaris announced the publication of a real-world study validating patient-reported outcome measures (PGI and AMRA) used in clinical trials for on-demand treatment of hereditary angioedema (HAE), supporting the endpoint hierarchy in its ongoing Phase 3 RAPIDe-3 trial of deucrictibant. The findings reinforce the patient-centric design of the trial and may influence future HAE treatment assessments.

  • Study validates PGI and AMRA instruments as reliable tools for assessing patient experience during HAE attacks.
  • Findings support the hierarchical endpoint structure in the Phase 3 RAPIDe-3 trial of oral deucrictibant for on-demand HAE treatment.
  • End of Progression™ was identified as the first meaningful milestone, followed by symptom relief and resolution.
  • Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland for bradykinin-mediated angioedema.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access